ÇÁ·Î±×·¥

ÀϽà : 2021³â 3¿ù 20ÀÏ(Åä) *½Ç½Ã°£ ¿Â¶óÀÎ ÄÁÆÛ·±½º

¡¡ Morning Scientific Symposium ÁÂÀå: °­ÁøÇü (¼­¿ï¼º¸ðº´¿ø)
08:50~09:30 A paradigm shift in ALK+NSCLC first-line treatment : clinical experience of ALUNBRIG¢ç ±èŹΠ(¼­¿ï´ëº´¿ø)
¡¡ Plenary Session¡¡¡¡
¡¡ Diagnosis & monitoring of lung cancer¡¡ ÁÂÀå: ±è½ÂÁØ (¼­¿ï¼º¸ðº´¿ø)
09:30~09:50 Non-invasive biomarkers in lung cancer management ¹ÚÂù±Ç (¿©Àǵµ¼º¸ðº´¿ø)
09:50~10:10 Recent progress of lung cancer screening¡¡ Àü°æ³à (â¿ø°æ»ó´ëº´¿ø)
10:10~10:30 New WHO classification of lung tumors ±è·ç½Ã¾Æ (ÀÎÇϴ뺴¿ø)
¡¡ Treatment of lung cancer ÁÂÀå: ±è»óÀ§ (¼­¿ï¾Æ»êº´¿ø)
10:30~10:50 Surgical role in the era of perioperative immune checkpoint inhibitor ±èÈ«°ü (»ï¼º¼­¿ïº´¿ø)
10:50~11:10 New data of precision oncology practice from WCLC 2020 ¹Î¿µÁÖ (¿ï»ê´ëº´¿ø)
11:10~11:30 Updated clinical trial data of immuno-oncology ±èÇý·Ã (¼¼ºê¶õ½ºº´¿ø)
11:30~11:40 Q&A¡¡
¡¡ Scientific Symposium ¡¡ ÁÂÀå: À̱âÇü (ÃæºÏ´ëº´¿ø)
11:40~12:30 Beyond becoming a SOC in mNSCLC treatment, Pembrolizumab now opens a new era of More TOMORROWs À̼¼ÈÆ (»ï¼º¼­¿ïº´¿ø)
12:30~13:00 Coffee Break
¡¡ Room A Room B Room C
Parallel Session Multidisciplinary: Expanding indication of local therapy in lung cancer

ÁÂÀå: ±è¿¬½Ç (¼­¿ï¼º¸ðº´¿ø)

¡¡ Imaging and Screening

ÁÂÀå: ±èÀ±Çö (Àü³²´ëº´¿ø)

13:00~13:20
Radiofrequency ablation as lung cancer treatment

Áø°ø¿ë (ÀüºÏ´ëº´¿ø)

¡¡ 13:00~13:25
Screening and early detection-lung cancer screening programs

ÀÓÀ籤 (°æºÏ´ëº´¿ø)

13:20~13:40
Radiotherapy in early stage and oligomers

ÀÓäȫ (°í·Á´ë¾È»êº´¿ø)

13:25~13:50
Screening and early detection -risk modelling and artificial intelligence

³²ÁÖ°­ (¼­¿ï´ëº´¿ø)

13:40~14:00
Limited surgery not limited to local disease

±èÇö±¸ (°í·Á´ë±¸·Îº´¿ø)

13:50~14:15
Screening and early detection -radiological risk stratification

ÀÌÁ¾Àº (Àü³²´ëº´¿ø)

14:00~14:20 Discussion 14:15~14:20 Discussion
Advanced NSCLC

ÁÂÀå: ½Éº´¿ë (¼ººó¼¾Æ®º´¿ø)

Pulmonology

ÁÂÀå: Àå½ÂÈÆ (ÇѸ²´ë¼º½Éº´¿ø)

Pathology & Biomarker Discovery

ÁÂÀå: À̰DZ¹ (±¹¸³¾Ï¼¾ÅÍ)

14:20~14:50
Immunotherapy

¹Ú°Ç¿í (°è¸í´ëµ¿»êº´¿ø)

14:20~14:40
Something new in Palliative and Supportive Care

¿©Ã¢µ¿ (ÀºÆò¼º¸ðº´¿ø)

14:20~14:40
The New WHO Classification of Lung Tumors

½ÉÈ¿¼· (¼¼ºê¶õ½ºº´¿ø)

14:40~15:00
Tumor Biology and Advances in Omics

ÀÌÁ¤Àº (Ãæ³²´ëº´¿ø)

14:40~15:00
Getting All NSCLCs Genotyped: How Can We Get to 100%?

±èÅÂÁ¤ (¿©Àǵµ¼º¸ðº´¿ø)

14:50~15:20
New data from rare EGFR Alterations

ÀÌÀ±±Ô (°­ºÏ»ï¼ºº´¿ø)

15:00~15:20
Technological Advances in Diagnostics for Lung Cancer

±èÇý·Ã (¿øÀڷº´¿ø)

15:00~15:20
Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non Small Cell Lung Carcinoma

ÃÖÀ±¶ó (»ï¼º¼­¿ïº´¿ø)

15:20~15:30Discussion ¡¡ 15:20~15:30 Discussion 15:20~15:30 Discussion
15:30~16:00 Coffee Break
Thoracic malignancies

ÁÂÀå: ÀÌ´ëÈ£ (¼­¿ï¾Æ»êº´¿ø)

Thoracic Surgical Oncology

ÁÂÀå: °­Ã¢Çö (¼­¿ï´ëº´¿ø)

Update in Radiation Oncology

ÁÂÀå: ¹®¼ºÈ£ (±¹¸³¾Ï¼¾ÅÍ)

16:00~16:20
SCLC

ÀÓ¼±¹Î (¼¼ºê¶õ½ºº´¿ø)

16:00~16:20
- Therapeutic strategies for metachronous multiple primary lung cancer
- Prognostic factors and strategies for metachronous second primary lung cancer

Á¶Á¾È£ (»ï¼º¼­¿ïº´¿ø)

16:00~16:20
Radiotherapy for LA-NSCLC

¼ÛÃ¢ÈÆ (ºÐ´ç¼­¿ï´ëº´¿ø)

16:20~16:45
Thymic Malignacy/Mesothelioma

¹Ú¼¼ÈÆ (»ï¼º¼­¿ïº´¿ø)

16:20~16:40
- Characterization and classification of oligometastatic disease
- Surgery as a component of local consolidative therapy

À̱ٵ¿ (¼­¿ï¾Æ»êº´¿ø)

16:20~16:40
New trends of radiotherapy in lung cancer

À±È«ÀÎ (¼¼ºê¶õ½ºº´¿ø)

16:45~17:00
New challenges during COVID-19

°­ÀºÁÖ (°í·Á´ë±¸·Îº´¿ø)

16:40~17:00
- Should role of surgery be re-evaluated in small cell lung cancer?
- Is there a role for surgery in stage I small cell lung cancer?

¹Ú¼º¿ë (¼¼ºê¶õ½ºº´¿ø)

16:40~17:00
Radiotherapy for SCLC and other thoracic tumors (mesothelioma / thymoma)

°ûÀ¯°­ (ÀÎõ¼º¸ðº´¿ø)

17:00~17:10 Discussion 17:00~17:10 Discussion 17:00~17:10 Discussion
Copyright (c) 2013 by Korean Society of Medical Oncology. All rights reserved.
03186 ¼­¿ïƯº°½Ã Á¾·Î±¸ »õ¹®¾È·Î 92 (½Å¹®·Î1°¡ 163) ±¤È­¹®¿ÀÇǽþƺôµù 2220È£ TEL : 02-735-2857 FAX : 02-735-2856 E-mail : ksmo@ksmo.or.kr